INOVIO Set to Showcase Innovations at Upcoming Scientific Conferences

INOVIO's Upcoming Conference Presentations

INOVIO Pharmaceuticals, a prominent biotechnology firm listed on NASDAQ under the ticker INO, is gearing up to present critical developments in DNA medicine at several prestigious scientific gatherings. Specializing in treatments aimed at diseases linked to the human papillomavirus (HPV), cancer, and various infectious diseases, the company is set to share ground-breaking data regarding its lead candidate, INO-3107.

The first major event on INOVIO's calendar is the National HPV Conference, taking place in Indianapolis, Indiana, on April 15, 2025. During this conference, INOVIO will deliver an oral presentation detailing the impressive results of its DNA immunotherapy, INO-3107, which has achieved a 72% overall response rate in its first year of treating recurrent respiratory papillomatosis caused by HPV-6 and HPV-11. Accompanying this presentation, a panel discussion moderated by Kim McClellan, President of the RRP Foundation, will delve into lessons learned and clinical advances in managing this condition.

Following this conference, INOVIO will participate in the World Vaccine Congress held in Washington, DC, on April 21. Here, INOVIO plans to introduce a novel technology involving DNA-encoded monoclonal antibodies (DMAbs™). This innovative approach marks a significant step in the development of next-generation DNA medicines, empowering the body to produce its own therapeutic agents. Additionally, on April 23, INOVIO will present again, focusing on the application of DNA immunotherapeutics in combating cancers and viral diseases.

Another highlight for INOVIO is its participation in the Festival of Biologics in San Diego, California, also on April 23. At this event, INOVIO will further discuss the advancements made with INO-3107 in the context of recurrent respiratory papillomatosis, offering insights into the utility of DNA medicines in treating such disorders.

Following these events, INOVIO plans to share the abstracts of the presentations on its official website, providing broader access to their findings.

About INOVIO

INOVIO Pharmaceuticals is at the forefront of biotechnology, dedicating its resources to the development and commercialization of DNA medicines. These innovations are designed to empower patients by teaching their bodies to create effective disease-fighting tools. The company's ongoing commitment to enhancing health through advanced technology illustrates its pivotal role in the life sciences sector.

To discover more about INOVIO and its initiatives, visit inovio.com.

For further inquiries, media representatives can contact Jennie Willson at 267-429-8567, or for investor relations, reach out to Peter Vozzo at ICR Healthcare via 443-213-0505.

In summary, INOVIO's presentations at these upcoming scientific conferences are set to highlight its commitment to pioneering advancements in biotechnology, especially in the fight against HPV-related illnesses, signaling a bright future for DNA medicines and patient care.